New approaches in the treatment of HIV/AIDS - focus on maraviroc and other CCR5 antagonists.

Ther Clin Risk Manag · 2008 · PMC2504054 · PMID 18728830

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

quite significantno p-value reported

Thus, in addition to further reassurance of maraviroc’s safety profile, the lack of HIV progression in the D/M group was quite significant and deserves additional investigation as concerns linger regarding the impact of X4-tropic virus.

also in 5,695 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.